IMV-4

IMV-4 is a preclinical bispecific antibody candidate being developed by ImmuVia for the treatment of hematologic malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL). The drug is engineered using ImmuVia's proprietary Cancerlysin™ platform, which is designed to create bispecific antibodies that facilitate targeted tumor cell destruction. While the specific molecular targets for IMV-4 have not been publicly disclosed, the Cancerlysin™ platform typically focuses on bispecific constructs that engage tumor-associated antigens and immune effector mechanisms to induce tumor cell lysis.